Charles River Laboratories International, Inc.
CRL
$155.46
$2.801.83%
NYSE
| 12/27/2025 | 09/27/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.06% | -2.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.06% | -2.64% | |||
| Cost of Revenue | 1.94% | 0.64% | |||
| Gross Profit | -6.61% | -8.19% | |||
| SG&A Expenses | 10.58% | -6.55% | |||
| Depreciation & Amortization | 235.77% | 6.70% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.20% | -0.74% | |||
| Operating Income | -70.33% | -12.18% | |||
| Income Before Tax | -437.27% | 22.10% | |||
| Income Tax Expenses | -156.28% | 68.99% | |||
| Earnings from Continuing Operations | -597.32% | 5.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 76.63% | -208.99% | |||
| Net Income | -608.17% | 4.01% | |||
| EBIT | -70.33% | -12.18% | |||
| EBITDA | 2.64% | -49.47% | |||
| EPS Basic | -608.16% | 3.87% | |||
| Normalized Basic EPS | -66.15% | -28.16% | |||
| EPS Diluted | -610.84% | 3.77% | |||
| Normalized Diluted EPS | -66.00% | -28.23% | |||
| Average Basic Shares Outstanding | 0.01% | 0.13% | |||
| Average Diluted Shares Outstanding | -0.42% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||